Corient Private Wealth LP Boosts Position in Avantor, Inc. $AVTR

Corient Private Wealth LP boosted its stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 176.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,760,605 shares of the company's stock after buying an additional 1,123,075 shares during the quarter. Corient Private Wealth LP owned approximately 0.26% of Avantor worth $17,430,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Private Management Group Inc. raised its stake in shares of Avantor by 50.4% during the fourth quarter. Private Management Group Inc. now owns 2,456,859 shares of the company's stock valued at $28,156,000 after acquiring an additional 823,572 shares in the last quarter. GSA Capital Partners LLP bought a new position in Avantor in the second quarter worth approximately $800,000. Oppenheimer Asset Management Inc. purchased a new position in Avantor during the 2nd quarter worth $805,000. Assenagon Asset Management S.A. increased its holdings in Avantor by 425.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company's stock worth $5,513,000 after purchasing an additional 450,801 shares during the period. Finally, Brickwood Asset Management LLP raised its position in Avantor by 6,891.9% during the 4th quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company's stock valued at $36,489,000 after purchasing an additional 3,138,504 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Stifel Nicolaus upped their target price on Avantor from $8.00 to $15.00 and gave the stock a "hold" rating in a report on Thursday, July 30th. UBS Group assumed coverage on Avantor in a research note on Wednesday, September 9th. They set a "neutral" rating and a $16.00 price target on the stock. Wolfe Research upgraded Avantor from a "strong sell" rating to a "hold" rating in a research note on Thursday, July 30th. Morgan Stanley lifted their price objective on Avantor from $10.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. Finally, TD Cowen reaffirmed a "hold" rating on shares of Avantor in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $12.47.

Avantor Stock Up 2.3%

Avantor stock opened at $15.15 on Tuesday. Avantor, Inc. has a 1-year low of $7.26 and a 1-year high of $15.93. The stock has a market capitalization of $10.25 billion, a price-to-earnings ratio of -18.04, a PEG ratio of 11.18 and a beta of 0.89. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. The business has a fifty day moving average price of $13.20 and a 200-day moving average price of $10.19.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.02. The firm had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The business's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities research analysts forecast that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

About Avantor

Avantor, Inc NYSE: AVTR is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.